Your browser doesn't support javascript.
loading
The impact of the COVID-19 vaccination programme on symptomatic and severe SARS-CoV-2 infection during a period of Omicron variant dominance in Ireland, December 2021 to March 2023.
Marron, Louise; Mateo-Urdiales, Alberto; O'Donnell, Joan; Robinson, Eve; Domegan, Lisa.
Afiliação
  • Marron L; European Centre for Disease Prevention and Control (ECDC) Fellowship Programme, Field Epidemiology path (EPIET), ECDC, Stockholm, Sweden.
  • Mateo-Urdiales A; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
  • O'Donnell J; Department of Infectious Diseases, Istituto Superiore di Sanità (Italian National Institute of Health), Rome, Italy.
  • Robinson E; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
  • Domegan L; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
Euro Surveill ; 29(28)2024 Jul.
Article em En | MEDLINE | ID: mdl-38994604
ABSTRACT
BackgroundAs Ireland prepared for an autumn 2023 COVID-19 vaccination booster campaign, there was concern that vaccine fatigue would affect uptake, which has been abating.AimThis study aimed to quantify the direct impact of the COVID-19 vaccination programme in Ireland on averted COVID-19-related outcomes including symptomatic presentations to primary care/community testing centres, emergency department (ED) presentations, hospitalisations, intensive care unit (ICU) admissions and deaths, in individuals aged ≥ 50 years, during Omicron dominance.MethodsWe conducted a retrospective observational COVID-19 vaccine impact study in December 2021-March 2023 in Ireland. We used national data on notified outcomes and vaccine coverage, as well as vaccine effectiveness (VE) estimates, sourced from the World Health Organization's live systematic review of VE, to estimate the count and prevented fraction of outcomes in ≥ 50-year-olds averted by the COVID-19 vaccination programme in this age group.ResultsThe COVID-19 vaccination programme averted 48,551 symptomatic COVID-19 presentations to primary care/community testing centres (36% of cases expected in the absence of vaccination), 9,517 ED presentations (53% of expected), 102,160 hospitalisations (81% of expected), 3,303 ICU admissions (89% of expected) and 15,985 deaths (87% of expected).ConclusionsWhen Omicron predominated, the COVID-19 vaccination programme averted symptomatic and severe COVID-19 cases, including deaths due to COVID-19. In line with other international vaccine impact studies, these findings emphasise the benefits of COVID-19 vaccination for population health and the healthcare system and are relevant for informing COVID-19 booster vaccination programmes, pandemic preparedness and communicating the reason for and importance of COVID-19 vaccination in Ireland and internationally.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Programas de Imunização / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Hospitalização Limite: Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Programas de Imunização / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Hospitalização Limite: Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article